Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Advanced Solid Tumor 6Carcinoma, Hepatocellular 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Advanced Solid Tumors 2Advanced Lung Cancer 2Urinary Bladder Neoplasms 1Treatment-naive Advanced Non-small Cell Lung Cancer 1Sarcoma 1Recurrence 1Mouth Neoplasms 1Melanoma 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1High-Risk Resectable NSCLC 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Anus Neoplasms 1Anal Canal Carcinoma 1Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy 1

Interventions

Temozolomide 94Radiotherapy 59Bevacizumab 59Radiosurgery 41Carboplatin 27Irinotecan 26Magnetic Resonance Spectroscopy 25Surgical Procedures, Operative 23Etoposide 22Carmustine 20Filgrastim 18Erlotinib Hydrochloride 17Cyclophosphamide 16Cisplatin 16Vincristine 15Lomustine 15Lapatinib 15Sorafenib 13Radiation 13Trastuzumab 12Nivolumab 12Imatinib Mesylate 12Thalidomide 11Surveys and Questionnaires 11Granulocyte Colony-Stimulating Factor 11Radiotherapy, Intensity-Modulated 10Aminolevulinic Acid 10temsirolimus 9Topotecan 9Thiotepa 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Brain Neoplasms × toripalimab × Clear all
NCT05021328 2025-02-07

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

Hubei Cancer Hospital

Phase 1 Completed
13 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡